Marex Group Limited (MRX) insider trading

{
  "status": "OK",
  "results": [
    {
      "tickers": [
        "MRX"
      ],
      "issuer_cik": "0001997464",
      "owner_cik": "0002057942",
      "accession_number": "0001193125-26-421660",
      "form_type": "4",
      "filing_date": "2026-10-14",
      "period_of_report": "2026-10-12",
      "issuer_name": "Marex Group Ltd",
      "issuer_trading_symbol": "MRX",
      "owner_name": "Tonucci Paolo",
      "is_director": false,
      "is_officer": true,
      "is_ten_percent_owner": false,
      "is_other": false,
      "officer_title": "See Remarks",
      "security_type": "non_derivative",
      "record_type": "transaction",
      "security_title": "Ordinary Shares",
      "transaction_timeliness": "O",
      "aff_10b5_one": true,
      "transaction_date": "2026-10-12",
      "transaction_code": "S",
      "equity_swap_involved": false,
      "transaction_shares": 15506,
      "transaction_price_per_share": 71.9819,
      "transaction_acquired_disposed": "D",
      "shares_owned_following_transaction": 1254065,
      "transaction_value": 1116151.3414,
      "direct_or_indirect": "D",
      "footnotes": [
        {
          "id": "F1",
          "description": "The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan entered into by the Reporting Person on October 22, 2025."
        },
        {
          "id": "F2",
          "description": "The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $71.39 to $72.37, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."
        }
      ],
      "remarks": "Chief Strategist and CEO, Capital Markets"
    },
    {
      "tickers": [
        "MRX"
      ],
      "issuer_cik": "0001997464",
      "owner_cik": "0002057942",
      "accession_number": "0001193125-26-421660",
      "form_type": "4",
      "filing_date": "2026-10-14",
      "period_of_report": "2026-10-12",
      "issuer_name": "Marex Group Ltd",
      "issuer_trading_symbol": "MRX",
      "owner_name": "Tonucci Paolo",
      "is_director": false,
      "is_officer": true,
      "is_ten_percent_owner": false,
      "is_other": false,
      "officer_title": "See Remarks",
      "security_type": "non_derivative",
      "record_type": "transaction",
      "security_title": "Ordinary Shares",
      "transaction_timeliness": "O",
      "aff_10b5_one": true,
      "transaction_date": "2026-10-12",
      "transaction_code": "S",
      "equity_swap_involved": false,
      "transaction_shares": 1160,
      "transaction_price_per_share": 72.6382,
      "transaction_acquired_disposed": "D",
      "shares_owned_following_transaction": 1252905,
      "transaction_value": 84260.31199999999,
      "direct_or_indirect": "D",
      "footnotes": [
        {
          "id": "F1",
          "description": "The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan entered into by the Reporting Person on October 22, 2025."
        },
        {
          "id": "F3",
          "description": "The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $72.42 to $72.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."
        },
        {
          "id": "F4",
          "description": "The number of ordinary shares reported herein includes (i) 20,628 shares underlying the Issuer's 2022 Annual Long Term Incentive Plan, and (ii) 220,746 shares underlying deferred bonus plan awards previously granted to the Reporting Person. Each award represents a contingent right to receive one (1) ordinary share of the Issuer upon vesting and settlement of the applicable award."
        }
      ],
      "remarks": "Chief Strategist and CEO, Capital Markets"
    }
  ]
}

// trimmed to 2 results

The response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.